Talukdar Joyeeta, Nayek Arnab, Gogoi Gayatri, Srivastava Tryambak P, Goel Isha, Sahoo Om Saswat, Dhar Ruby, Karmakar Subhradip
Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Department of Pathology, Assam Medical College, Dibrugarh, Assam, India.
Discov Oncol. 2025 Aug 25;16(1):1615. doi: 10.1007/s12672-025-03437-8.
This study investigates the interplay between the Atypical chemokine receptors (ACKR1)/Decoy receptor for chemokines (DARC) and key molecular markers, including CCL8, c-MYC, ALDH1, and CHEK2, in breast cancer. DARC has been implicated in various aspects of cancer progression, including tumor growth, angiogenesis, and metastasis. By analyzing the expression patterns of these markers in breast cancer tissues, we aim to understand their collective impact on tumor behaviour and identify potential therapeutic targets. Our findings reveal complex interactions between DARC and these molecular markers, suggesting their synergistic roles in promoting or repressing breast cancer progression. Understanding these relationships could lead to developing more effective and personalized therapeutic strategies.
本研究调查了非典型趋化因子受体(ACKR1)/趋化因子诱饵受体(DARC)与关键分子标志物(包括CCL8、c-MYC、ALDH1和CHEK2)在乳腺癌中的相互作用。DARC已被证明与癌症进展的各个方面有关,包括肿瘤生长、血管生成和转移。通过分析这些标志物在乳腺癌组织中的表达模式,我们旨在了解它们对肿瘤行为的综合影响,并确定潜在的治疗靶点。我们的研究结果揭示了DARC与这些分子标志物之间的复杂相互作用,表明它们在促进或抑制乳腺癌进展中具有协同作用。了解这些关系可能会导致开发出更有效和个性化的治疗策略。